

Mr. Rodrigo Buenaventura  
Head of Secondary Markets  
Spanish Stock Exchange Commission  
Miguel Ángel, 11, 1st floor  
28010 Madrid

## **RELEVANT FACT**

Valencia (Spain), 15th April 2010

Dear Sir,

In accordance with Article 82 of Law 24/1988, 28th July, relative to the regulation of the stock market, and in relation to the Relevant Fact submitted to your attention last March 31th, Natraceutical, S.A. hereby informs you that the company has concluded today the refinancing of its bank debt after the subscription of the refinancing agreement of 100% of the company's financial debt.

The agreement calls for the long-term refinancing of all of the company's debt and the provision of new funds through a syndicated loan with a single maturity in 2013. The total amount refinanced is 77.9 million euro, which includes 4.4 million in new funding to strengthen operating cash flow.

The lead banks in the refinancing were: Banco de Sabadell, Banco de Valencia, Caixa d'Estalvis de Catalunya, Caja de Ahorros de Galicia, Caja de Ahorros de Valencia, Castellón y Alicante, Bancaja, and Caja de Ahorros del Mediterráneo.

The company was assisted by ING, as financial advisor, and the law firm J & A Garrigues Abogados, as legal advisor. Similarly, Ernst & Young acted as an independent validator of the business plans of the company.

With this design, Natraceutical will have sufficient financial muscle to strengthen the development of Forté Pharma as a leading brand in Europe in the field of nutritional supplements and to give value to the recent merger of its Ingredients Division with the French Naturex, in which Natraceutical currently holds 34%.

Under the new business structure, Natraceutical will consolidate earnings with Forté Pharma and with Naturex, the latter using the equity method reflecting the 34% stake.



Yours faithfully,

M<sup>a</sup> José Busutil Santos  
Secretaria del Consejo de Administración  
Natraceutical, S.A.